Current role of diethylstilbestrol in the management of advanced prostate cancer

摘要: What's known on the subject? and What does study add? Diethylstilbestrol (DES) has been found to have anti-tumour properties clinical effectiveness in prostate cancer that is resistant first-line hormonal therapy. This review low-dose DES efficacy with limited cardiovascular side effects should be considered for secondary hormone manoeuvres. The aim of this was describe most recent data from contemporary trials diethylstilbestrol better determine its current role advanced treatment as new therapies emerge. Relevant studies using 1 mg castrate-resistant (CRPC) were identified literature, trial databases, websites conference abstracts. The safety outcomes summarized. CRPC produced a biological response (change PSA level) improved median survival patients when used second-line therapy after standard androgen deprivation bicalutamide LHRH analogues. These findings low doses DES. 1-mg dose associated reduced toxicity, including fewer thromboembolic events. Low-dose appears safe effective before initiating chemotherapy. cost/efficiency ratio may encourage physicians consider option chemotherapy non-symptomatic CRPC.